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Although recent evidence demonstrates that Ras
causes transformation by activation of multiple down-
stream pathways, the specific role of non-Raf effector
pathways is presently unknown. Although Ras causes
activation of the Jun NH2-terminal kinases (JNKs) via a
Raf-independent pathway, the contribution of JNK ac-
tivation to Ras transformation and the effector that me-
diates JNK activation have not been established. We
observed that a dominant negative mutant of SEK1/
JNKK, an activator of JNKs, selectively inhibited onco-
genic Ras activation of JNK and Ras transformation, but
not Ras activation of the p42 mitogen-activated protein
kinase. In contrast, overexpression of wild type SEK1
enhanced Ras activation of JNK and transforming activ-
ity. Thus, JNK activation promotes Ras transformation.
Furthermore, a dominant negative mutant of p120 GAP
(designated N-GAP), a candidate Ras effector, blocked
Ras, but not Raf, transformation and blocked Ras, but
not Rac, activation of JNK. Since N-GAP overexpression
reduced the association of p190 Rac/Rho GAP with en-
dogenous p120 GAP, N-GAP may form nonproductive
complexes with components critical for p120 GAP func-
tion. In summary, p120 GAP may function as an effector
for Ras activation of JNK and Ras transformation.
Ras proteins are GDP/GTP-regulated switches that relay the
signals mediated by diverse extracellular stimuli (1, 2) to acti-
vate two distinct mitogen-activated protein kinase (MAPK)1
cascades (3, 4). Activated Ras complexes with and promotes the
activation of Raf serine/threonine kinases, which then activate
MAPK kinases (MEKs), which in turn activate the p42/p44
MAPKs (also called ERKs). The central role of the Raf/MEK/
ERK pathway in Ras-mediated transformation is supported by
the observations that kinase-deficient mutants of Raf-1, MEKs,
and ERKs are potent inhibitors of Ras transformation, whereas
constitutively activated mutants of Raf-1 or MEK cause tumor-
igenic transformation (5–11). Ras also activates a second Raf-
independent kinase cascade that leads to activation of JNKs
(also called SAPKs) (12–14). However, whether JNK activation
contributes to Ras transformation and what effector mediates
Ras activation of JNKs are presently unresolved.
Recent observations suggest that Ras may mediate its trans-
forming actions by stimulating both Raf-dependent and Raf-
independent signaling pathways. For example, there is evi-
dence that the function of Rho family proteins is necessary for
full Ras transforming activity (15–18). Furthermore, effector
domain mutants of Ras, that are defective in Raf-1 activation,
still retain the ability to cause tumorigenic transformation of
NIH 3T3 cells, possibly via activation of Rho family proteins
and JNK (19–21). Finally, the identification of non-Raf candi-
date Ras effectors provides additional support for the existence
of Raf-independent Ras signaling pathways (22–24). These in-
clude the two Ras GTPase activating proteins (p120 and NF1
GAPs) (25–31), guanine nucleotide exchange factors for Ral
proteins (32–34), and phosphatidylinositol-3-OH kinase (35).
Presently, the contribution of these candidate effectors to
Ras signal transduction and transformation has not been
determined.
Although there is evidence that p120 GAP functions both as
a negative regulator and downstream effector of Ras, the pre-
cise nature of the second role remains unresolved (25–31). The
COOH terminus contains the catalytic domain that binds to
Ras and promotes the hydrolysis of bound GTP. Whereas little
is known about the functional role of the NH2 terminus of p120
GAP, the presence of protein-protein interaction domains such
as the Src homology 2 and 3 motifs (SH2 and SH3), as well as
the pleckstrin homology domain, suggests that p120 GAP may
serve as an adaptor to promote the formation of complexes with
activated Ras. Consistent with this, GAP-associated proteins
that interact with the SH2 or SH3 sequences have been iden-
tified (36).
Since p120 GAP may serve both a negative regulatory and a
downstream effector function for Ras, experiments aimed at
defining an effector function of p120 GAP based on overexpres-
sion are very difficult to interpret. Therefore, much of the
information implicating p120 GAP as an effector for Ras sig-
naling and transformation has come from studies in which
NH2-terminally truncated mutants of p120 GAP (e.g. N-GAP)
that lack the GTPase catalytic activity have been shown to
exhibit a variety of cellular activities (36). For example, we and
others showed that N-GAP fragments could block Ras-medi-
ated signaling and transformation (25, 28, 29, 31). Therefore,
N-GAP may serve as a dominant inhibitory mutant of p120
GAP downstream effector function.
p120 GAP may mediate Ras signaling pathways that modu-
late actin cytoskeletal organization (37). Since Rho family pro-
teins are modulators of actin organization and activate JNK
(38, 39), we determined if JNK activation is important for Ras
transformation and if p120 GAP may mediate Ras activation of
JNK. First, we observed that dominant negative mutants of
SEK1 (an activator of JNK), which selectively blocked Ras
activation of JNK but not ERKs, inhibited Ras transformation.
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Second, we found that catalytically inactive fragments of p120
GAP blocked Ras, but not Rac1, activation of JNK, and blocked
Ras, but not Raf, transformation of NIH 3T3 cells. We suggest
that p120 GAP may mediate Ras activation of JNK and that
JNK activation contributes to Ras transformation.
EXPERIMENTAL PROCEDURES
Molecular Constructs—Expression vectors encoding wild type and
kinase-deficient mutants of human SEK1 were provided by M. Karin
and D. Templeton. pZIP-NeoSV(x)1 retrovirus expression vector con-
structs encoding NH2-terminal fragments of human p120 GAP were
described previously (28). N-GAP contains p120 GAP residues 1 to 666,
whereas N-GAP/CAAX represents N-GAP sequences together with ad-
dition of the COOH-terminal 18-amino acid plasma membrane-target-
ing sequences from human Ki-Ras4B (28). pCGN-hyg expression vector
constructs of N-GAP and N-GAP/CAAX were also generated, where
expression of NH2-terminal hemagglutinin (HA) epitope-tagged N-GAP
proteins were expressed off the cytomegalovirus promoter. Expression
vectors encoding FLAG epitope-tagged JNK, HA epitope-tagged p42
MAPK/ERK2, and HA-tagged Ha-Ras(12V) (pDCR) were described pre-
viously and provided byM. Karin, M. Weber, andM.White, respectively
(19, 40). pZIP-rac1(61L), pUC-Ha-ras(12V) and pZIP-raf22W encode
transforming mutants of human Rac1, Ha-Ras and Raf-1, respectively,
and have been described previously (20, 41). pGEX-jun encodes a glu-
tathione S-transferase (GST)-Jun-(1–79) fusion protein (provided by
M. Karin) (42).
Cell Culture and Transformation Analyses—NIH 3T3 mouse fibro-
blasts were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% calf serum, and plasmid DNAs were introduced by
calcium phosphate precipitation by procedures described previously
(43). To determine the role of JNK activation in Ras transformation,
cultures of NIH 3T3 cells were co-transfected with plasmid constructs
encoding oncogenic Ras(12V) (10 ng/dish), together with either empty
vector or vectors encoding wild type or mutant SEK1 (0.5 mg/dish).
Kinase-deficient mutants of SEK1 contain mutations in the ATP bind-
ing site (Lys 3 Arg or Ala) and have been shown to selectively inhibit
JNK, but not ERK, activation by anisomycin, Abl, Rac, or ceramide
(44–47). To determine the role of p120 GAP in Ras and Raf transfor-
mation, NIH 3T3 cells were co-transfected with 25 ng of pUC-H-
ras(12V) or 50 ng of activated Raf-1 (pZIP-raf22W) and 2 mg of pZIP
encoding N-GAP or N-GAP/CAAX. All transfections were performed in
triplicate, and the appearance of transformed foci was quantitated after
14 to 16 days.
JNK and MAPK Kinase Assays—To determine the ability of the wild
type or mutant SEK1 to modulate oncogenic Ras activation of JNK or
MAPK, COS-7 cells were transfected with 2 mg of FLAG epitope-tagged
JNK or hemagglutinin (HA) epitope-tagged p42 MAPK/ERK2, 2 mg of
pDCR Ha-ras(12V) (HA-tagged), and 2 mg of empty vector, or vector
encoding wild type or dominant negative SEK1. To assess the ability of
N-GAP to modulate oncogenic Ras or Rac1 activation of JNK or p42
MAPK, COS-7 cells were transfected with 1.5 mg of HA-MAPK or FLAG
epitope-tagged JNK, 1 mg of pDCR-rasH(12V) or 1.5 mg of pCGN-
rac1(61L), and 3 mg of a pcDNA1 construct encoding N-GAP/CAAX.
Forty-eight h after transfection, the cells were shifted to 0.5% serum
overnight. After an additional 15 h, the cells were lysed and protein
levels were equalized before immunoprecipitating JNK or MAPK/ERK
from the extracts with 2 ml of anti-FLAG (Kodak Eastman) or anti-HA
(Babco) antibody. The appropriate immunoprecipitate was assayed for
JNK activity on GST-Jun fusion protein or MAPK activity on myelin
basic protein (MBP), using procedures described previously (20) and
gels quantitated by scintillation counting of excised bands. The pres-
ence of similar levels of FLAG-JNK1 or HA-MAPK protein was con-
firmed by Western blot analysis using anti-FLAG or -HA monoclonal
antibodies, respectively.
Determination of p190 Rac/Rho GAP Association with p120
GAP—To determine the consequences of N-GAP overexpression on the
degree of p190 Rac/Rho GAP association with endogenous p120 GAP,
COS-7 cells were transiently transfected with pDCR-Ha-ras(12V) and
either the pCGN-hyg empty vector or pCGN-hyg encoding N-GAP. After
48 h, the cells were lysed and cleared of N-GAP by immunoprecipitating
with 3 ml of anti-HA antibody. Endogenous full-length p120 GAP was
then immunoprecipitated from the cleared lysates with an anti-p120
Ras GAP monoclonal (BF48, Santa Cruz Biotech). Levels of p120 GAP
and of co-precipitated p190 Rho GAP were analyzed byWestern blotting
(p190 antiserum provided by S. Parsons).
RESULTS AND DISCUSSION
Kinase-deficient SEK1 Selectively Impairs Oncogenic Ras Ac-
tivation of JNK, but Not p42 MAPK, and Ras Transformation—
Since JNK is a component of the stress-activated pathway, it
has been proposed that JNK activation mediates an apoptotic,
rather than growth-proliferative, response (46–48). On the
other hand, a direct correlation was observed between the level
of JNK activation and the transforming potency of a panel of
Ras mutants (8). Furthermore, JNK is an activator of the Jun
transcription factor, and Jun function is necessary for Ras
transformation of fibroblast cells (49, 50). To assess the contri-
bution of JNK activation to Ras transformation, we determined
if dominant negative mutants of the JNK activator, SEK1/
JNKK (13, 44, 51, 52), could block Ras transforming activity.
Kinase-deficient mutants of SEK1 have been shown previously
to selectively block JNK activation by a variety of stimuli (44,
45, 47). First, we wanted to determine if dominant negative
SEK1 could selectively block oncogenic Ras activation of JNK,
but not ERK. We observed that transient transfection analyses
showed that co-expression of the kinase-deficient SEK1(KR)
mutant blocked oncogenic Ras activation of JNK1 (Fig. 1A),
whereas co-expression of SEK1(WT) greatly potentiated JNK1
activation. In contrast, SEK1(KR) did not block Ras activation
of p42 MAPK/ERK2 (Fig. 1B). Thus, dominant negative SEK1
is not an inhibitor of the Raf/MEK/MAPK pathway. These
results are concordant with those described previously, where
dominant negative SEK1 selectively blocked transforming Abl
activation of JNK, but not ERK (44).
Next, we determined if dominant negative SEK1 inhibition
of JNK activation would alter Ras(12V) transforming activity.
Whereas co-transfection of SEK1(WT) caused an enhancement
FIG. 1. SEK1(KR) dominant negative inhibition of oncogenic Ras(12V) activation of JNK, but not ERKs, and inhibition of Ras(12V)
focus-forming activity. A, whereas co-expression of SEK1(WT) potentiated, SEK1(KR) blocked oncogenic Ras(12V) activation of JNK1. B,
co-expression of SEK1(KR) did not inhibit Ras activation of p42 MAPK in transiently transfected COS-7 cells. C, co-expression of the mutant
SEK1(KR), but not wild type SEK1, blocked oncogenic Ras(12V) focus formation in transfected NIH 3T3 cells. Similar results were obtained in
three separate experiments.
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of Ras(12V) focus-forming activity, co-transfection of SEK1
(KR) caused a very significant (80 to 90%) inhibition of
Ras(12V) focus-forming activity (Fig. 1C). Thus, JNK activa-
tion is necessary for full Ras transformation. It has been shown
previously that dominant negative mutants of Raf, MEK, and
ERK also inhibit Ras transformation. Therefore, Ras activation
of JNKs and ERKs are complementary, and their action to-
gether promotes Ras transformation. This contrasts with the
opposing effects of ERK and JNK on apoptosis in PC12 pheo-
chromocytoma cells (46). In these studies, apoptosis induced by
nerve growth factor withdrawal was associated with increased
JNK, but decreased ERK, activation. However, constitutive
activation of the MEK/ERK pathway prevented apoptosis in-
duced by epidermal growth factor withdrawal.
The importance of JNK activation, in the absence of ERK
activation, for Ras transformation is suggested by our recent
observation that effector domain mutants of oncogenic Ras that
are impaired in activation of the Raf/MEK/ERK pathway, but
still activate JNK, retain the ability to cause tumorigenic
transformation of NIH 3T3 cells. Furthermore, constitutively
activated mutants of Rac or Dbl family proteins (e.g. Dbl and
Ost) are activators of JNK, but not ERK (14, 45, 53), yet cause
growth transformation of NIH 3T3 cells. Thus, the conse-
quences of JNK activation on cell behavior may be cell type-
specific, causing growth (NIH 3T3), apoptosis (PC12, U937
leukemia, and others) or differentiation (12, 46–48, 54). The
consequences of JNK activation are also likely to be influenced
by the action of concurrent signaling events such as ERK
activation (46).
N-GAP Selectively Impairs Oncogenic Ras, but Not Rac1,
Activation of JNK—Ras, but not Raf, causes direct activation of
JNKs (13, 14). However, the effector that mediates Ras activa-
tion of JNK has not been established. Although there is evi-
dence that p120 GAP can serve as an effector for Ras signaling,
the precise pathways that may be controlled by p120 GAP have
not been established. Therefore, we next determined if p120
GAP functions as a downstream effector to mediate JNK acti-
vation via a Raf/MEK/ERK-independent pathway.
We and others showed previously that expression of NH2-
terminal fragments of p120 GAP, that lack the COOH-terminal
catalytic domain (designated N-GAP), inhibited Ras-mediated
signaling and transformation (25, 28, 31). Thus, N-GAP may
function as a dominant negative mutant of p120 GAP. Since we
found previously that a membrane-targeted version of N-GAP
(designated N-GAP/CAAX) was slightly enhanced in this inhib-
itory action, we used both N-GAP and N-GAP/CAAX mutant
FIG. 2. N-GAP inhibition of oncogenic Ras(12V), but not
DRaf(22W), transforming activity. NIH 3T3 cells were co-trans-
fected with expression vectors encoding transforming Ha-Ras(12V) or
Raf-1(22W) mutant proteins, and either with the pZIP empty vector, or
with pZIP vectors encoding N-GAP or N-GAP/CAAX and the appear-
ance of transformed foci scored after 14–16 days. Data shown are the
average of three separate assays and are expressed as relative focus-
forming units (FFU) normalized to the activities of oncogenic Ha-
Ras(12V) or DRaf(22W).
FIG. 3. N-GAP fails to inhibit oncogenic Ras(12V) activation of
p42 MAPK. COS-7 cells were co-transfected with expression vectors
encoding HA-MAPK/ERK, Ha-Ras(12V), and N-GAP/CAAX. Forty-
eight h after transfection, the cells were harvested and used for MAPK
kinase assays that were performed as described under “Experimental
Procedures.” Data shown are representative of three separate determi-
nations. A, quantitation of phosphorylation of MBP shown in B; B,
incorporation of 32P into MBP; C, Western blot analysis using anti-HA
antibody to quantitate HA-MAPK/ERK expression.
FIG. 4. N-GAP inhibition of oncogenic Ras, but not Rac1, acti-
vation of JNK. COS-7 cells were transfected as described above with
expression vectors encoding FLAG epitope-tagged JNK, Ha-Ras(12V),
Rac1(61L), and N-GAP/CAAX as indicated. Serum-starved cell lysates
were equalized for protein concentration and then immunoprecipitated
with anti-FLAG antibody (Kodak-Eastman). A, quantitation (above
background) of the average of two separate assays for GST-Jun phos-
phorylation (B) was measured as described in Fig. 1A; C, Western blot
of FLAG-JNK using anti-FLAG antibody.
FIG. 5. N-GAP reduction of p190 Rho GAP association with
p120 GAP. COS-7 cells were transiently transfected with pDCR-Ha-
ras(12V) and either the pCGN-hyg empty vector or pCGN-hyg encoding
N-GAP. After 48 h, the cells were lysed and cleared of N-GAP by
immunoprecipitating with 3 ml of anti-HA antibody. The cleared lysates
were then immunoprecipitated with an anti-p120 Ras GAP monoclonal,
and the immunoprecipitates were analyzed by Western blotting for the
levels of p120 GAP and co-precipitated p190 Rac/Rho GAP (p190 anti-
serum provided by S. Parsons).
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proteins for our studies. First, we determined that co-expres-
sion of N-GAP blocked oncogenic Ras(12V), but not DRaf(22W),
focus-forming activity in NIH 3T3 transformation assays (Fig.
2). Thus, N-GAP inhibition of Ras transformation is specific
and may involve antagonism of pathways distinct from those
required to cause Raf transformation.
The failure of N-GAP to block Raf transformation suggested
that N-GAP inhibition of Ras transformation was a conse-
quence of inhibition of a Ras-mediated, Raf-independent path-
way. Consistent with this, we found that co-expression of N-
GAP did not block oncogenic Ras activation of p42 MAPK/
ERK2 (Fig. 3). Thus, N-GAP inhibition of Ras transformation is
not a consequence of inhibition of the Raf/MEK/ERK pathway.
These observations are similar to those of Tocque and col-
leagues (55), who found that an anti-p120 GAP monoclonal
antibody blocked oncogenic Ras-induced germinal vesicle
breakdown, but not ERK activation, in Xenopus oocytes.
Since it has been proposed that p120 GAP may mediate Ras
activation of Rho family proteins, and consequently, JNK acti-
vation, we determined if N-GAP could inhibit Ras activation of
JNK. We observed that co-expression of N-GAP blocked onco-
genic Ras(12V) activation of JNK. In contrast, N-GAP failed to
block the ability of a constitutively activated mutant of
Rac1(12V) to activate JNK (Fig. 4). Thus, p120 GAP may func-
tion as an effector to mediate Ras activation of JNK. Since Ras
activation of JNK is dependent on Rac function (45), these
observations suggest that p120 GAP serves to connect Ras with
Rac to cause activation of JNK. However, we do not exclude the
possibility that Ras can also activate JNK by other candidate
effectors such as MEKK1 and phosphatidylinositol-3-OH ki-
nase (35, 56).
N-GAP Antagonizes p190 Rac/Rho GAP Association with
Endogenous p120 GAP—N-GAP contains several domains that
may mediate protein-protein interactions, such as the Src ho-
mology 2 and 3 (SH2 and SH3) domains, as well as pleckstrin
homology and other candidate motifs. Thus, N-GAP may in-
hibit Ras function by its formation of nonproductive complexes
with components that are important for mediating p120 GAP
downstream function. For example, the two SH2 domains are
required for p120 GAP interaction with the p190 Rho/Rac GAP
(57).
Since p190 functions as a Rho/Rac GAP (58), it constitutes a
logical connection to promote Ras activation of a Rho family
protein which then causes activation of JNKs. Therefore, we
determined if co-expression of N-GAP decreased p190 associa-
tion with endogenous p120 GAP. Whereas immunoprecipita-
tion of p120 GAP from control untransfected COS-7 cells re-
sulted in the co-precipitation of p190, the degree of p190 co-
precipitation was reduced significantly in cells expressing
exogenously introduced N-GAP (Fig. 5). Thus, N-GAP can an-
tagonize the ability of proteins to associate with p120 GAP.
Whether formation of a complex between Ras:p120 GAP and
p190 GAP serves to inactivate its Rac/Rho GAP activity, to lead
activation of Rho family proteins, remains to be determined.
Whether p120 GAP association modulates p190 GAP activity,
whether p190 GAP overexpression overcomes N-GAP inhibi-
tory action, and whether an N-GAP mutant that fails to bind
p190 GAP has lost the ability to block Ras transformation are
experiments that may help address this question.
In summary, recent studies have shown that oncogenic Ras
causes transformation by activation of Raf-dependent and Raf-
independent pathways (19–21). Thus, there has been a re-
newed interest in defining the involvement of other Ras-bind-
ing proteins in mediating Ras signaling and transformation
(22–24). Our observations implicate p120 GAP as an effector
for mediating a Raf-independent signaling pathway that
causes JNK activation, and that JNK activation is essential for
full Ras transforming activity. These results further emphasize
the complex nature of Ras signal transduction and demon-
strate that Ras mediates its transforming actions through ac-
tivation of multiple effector-mediated signaling pathways.
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